PF-07899895 / Pfizer - LARVOL DELTA

A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults (clinicaltrials.gov) - P1 | N=37 | Terminated | Sponsor: Pfizer | N=53 ➔ 37 | Trial completion date: Feb 2026 ➔ Oct 2025 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2026 ➔ Oct 2025; Study was terminated early . This decision was not due to any safety concerns associated with PF-07899895 but rather due to a business decision.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Development of colon-targeted pan-SIK inhibitor PF-07899895 for the treatment of IBD (ACS-Fall 2025) - "This presentation will describe the discovery of a novel colon-targeted pan-SIK inhibitor. Utilizing structure-based drug design from existing internal chemical equity, a lead optimization campaign provided a potent, soluble, and permeable pan-SIK inhibitor clinical candidate with demonstrated efficacy in vivo."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Pfizer | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Jun 2025 | Trial primary completion date: Aug 2024 ➔ Jun 2025

Enrollment open • Trial completion date • Trial primary completion date

A Study to Learn How Different Amounts and Forms of the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults (clinicaltrials.gov) - P1 | N=53 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed